EDIT
$2.46
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
Recent News
Is Editas Medicine Going to $0?
The biotech could run out of funding before it can launch a single product.
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401
Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill and CFO Amy Parison. The company emphasized a platform centered on intravenous delivery of CRISPR c
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +77.78% and +280.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Editas: Q4 Earnings Snapshot
CAMBRIDGE, Mass. AP) — Editas Medicine Inc. EDIT) on Monday reported a loss of $5.6 million in its fourth quarter.